Pharma Equity Group A/S Class A PEG

As of late April 2026, European markets have been navigating a challenging landscape marked by geopolitical tensions and fluctuating economic indicators. Despite these hurdles, opportunities abound for investors willing to explore beyond the mainstream indices. Penny stocks, though often considered niche investments, can offer intriguing growth potential when they are backed by sound financial fundamentals. In this article, we will examine three European penny stocks that stand out for their...

The Board of Directors' resolution on the issuance of convertible loans April 28, 2026Announcement no. 6 The Board of Directors of Pharma Equity Group has decided to issue convertible loans in accordance with the authorisation in the Company's Articles of Association under item 4.3.A. The convertible loans allow Pharma Equity Group to borrow up to DKK 9.632.073. In connection with this issuance, existing convertible loans of nominal DKK 7.153.410 issued October 1, 2025. The main terms and condit

Proceedings of the Annual General Meeting of Pharma Equity Group A/S 17 April 2026Company Announcement no. 5 Pharma Equity Group A/S held its annual general meeting on 16 April 2026 at 3:30 pm CEST at Wihlborgs Kantiner, Slotsmarken 15, DK-2970 Hørsholm. The Chairman of the Board of Directors, Christian Vinding Thomsen, welcomed the shareholders and informed the meeting that the Board of Directors had resolved that the general meeting be conducted in Danish and had proposed Christian Vinding Tho

25 March 2026 Announcement no. 4 Notice convening the annual general meeting in Pharma Equity Group A/S The board of directors hereby convenes the annual general meeting in Pharma Equity Group A/S (“PEG” or the “Company”) to be held on: 16 April 2026, at 3.30 PM CEST at Wihlborgs CanteensSlotsmarken 15DK-2970 Hørsholm The agenda for the annual general meeting is as follows: The board of directors' report on the Company's activities in the past yearPresentation of the audited annual report for ap

25 March 2026 Announcement no. 3 Pharma Equity Group A/S - Annual Report 2025 Pharma Equity Group A/S - Annual Report 2025 – Highlights of the year Today, the Board of Directors of Pharma Equity Group A/S reviewed and approved the Company’s Annual Report for 2025, the key highlights of which are as follows: In 2025, Reponex Pharmaceuticals A/S obtained regulatory approval to initiate a pivotal Phase 2 trial of RNX-011 for the treatment of secondary bacterial peritonitis.In 2025, RNX-051 was furt

UPDATE OF THE FINANCIAL CALENDAR FOR 2026 Hørsholm 18 March 2026 Company announcement no 2 Pharma Equity Group A/S updates its financial calendar for 2026. For technical reasons, the publication of the annual report is being postponed from 18 March 2026 to 25 March 2026. The date of the annual general meeting remains unchanged at 16 April 2026. Pharma Equity Group2026 Financial Calendar ​March 4Deadline for shareholder proposals - Annual General meeting​ ​March 25 ​Annual Report 2025​ April 16An